Allurion Technologies (ALUR) Registration Filing summary
Event summary combining transcript, slides, and related documents.
Registration Filing summary
16 Dec, 2025Offering details and pricing
Registration statement filed for up to $100,000,000 of securities, including common stock, preferred stock, debt securities, warrants, units, subscription rights, and stock purchase contracts, to be offered separately or together, in series, at prices and terms to be set in future prospectus supplements.
Securities may be issued in unspecified numbers or principal amounts, with the structure and terms determined at the time of each offering.
Estimated SEC registration fee is $15,310; other issuance and distribution expenses are not specified and will depend on the nature and volume of securities issued.
Management team and governance
Registration statement signed by CEO, Shantanu Gaur, and other directors including Omar Ishrak, Krishna Gupta, Michael Davin, Larson Douglas Hudson, Keith Johns, Nicholas Lewin, and Milena Alberti-Perez.
Indemnification agreements in place for directors and executive officers, providing for advancement of expenses and broad indemnity to the fullest extent permitted by law.
Risk factors and disclosures
Indemnification for directors and officers is subject to limitations under Delaware law and may not be enforceable if deemed against public policy by the SEC.
Undertakings include commitments to update the registration statement for material changes and to remove unsold securities from registration.
Latest events from Allurion Technologies
- Innovative gastric balloon and digital platform target obesity with strong growth and U.S. expansion ahead.ALUR
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Innovative weight loss balloon and digital platform fuel growth, with U.K. reimbursement and U.S. expansion.ALUR
Jefferies 2024 Global Healthcare Conference1 Feb 2026 - Q2 revenue up 25% sequentially, but France suspension and NYSE risks weigh on outlook.ALUR
Q2 20241 Feb 2026 - Q3 revenue dropped 71% as AI sales soared and restructuring targets 2025 profitability.ALUR
Q3 202414 Jan 2026 - Up to 5,988,024 shares registered for resale, with $5M potential proceeds from warrant exercises.ALUR
Registration Filing9 Jan 2026 - 2024 revenue reached $32.1M, with cost cuts and growth in GLP-1 combination therapy.ALUR
Q4 202426 Dec 2025 - Allurion pivots to B2B2C, cuts costs, and eyes FDA approval for US launch in 2026.ALUR
TD Cowen 45th Annual Healthcare Conference26 Dec 2025 - Shelf registration for up to $100M supports global obesity platform expansion amid high risks.ALUR
Registration Filing16 Dec 2025 - Registering 6.1M+ shares for resale, with up to $19.7M in potential warrant proceeds.ALUR
Registration Filing16 Dec 2025